التفاصيل البيبلوغرافية
| العنوان: |
Evaluation of Vav3.1 as prognostic marker in endometrial cancer. |
| المؤلفون: |
Boesch, Maximilian, Sopper, Sieghart, Marth, Christian, Fiegl, Heidi, Wiedemair, Annemarie, Rössler, Julia, Hatina, Jiri, Wolf, Dominik, Reimer, Daniel, Zeimet, Alain G. |
| المصدر: |
Journal of Cancer Research & Clinical Oncology; Oct2018, Vol. 144 Issue 10, p2067-2076, 10p |
| مصطلحات موضوعية: |
GUANINE nucleotide exchange factors, OVARIAN cancer, CANCER cells, CANCER treatment, CANCER chemotherapy |
| مستخلص: |
Purpose: Vav3 is a guanine nucleotide exchange factor that regulates the activity of Rho/Rac family GTPases. In a study on ovarian cancer, we recently demonstrated pronounced prognostic and predictive value of Vav3.1, a specific truncation variant of the parental Vav3 gene. Here, we sought to investigate the role of Vav3.1 in the most prevalent gynecological tumor entity, endometrial cancer.Methods: Vav3.1 transcript levels were determined in a large cohort of endometrial cancer patients using variant-specific PCR (n = 239), and non-malignant endometrial tissue served as control (n = 26). Expression levels of Vav3.1 were stratified according to established clinicopathological characteristics and correlated to long-term patient survival (average follow-up of > 7.5 years). Type 1 and type 2 cancers were separately investigated.Results: While Vav3.1 was markedly overexpressed in endometrial cancer tissue, we could not detect associations with clinical parameters related to prognosis, such as FIGO stage and tumor grade. Kaplan-Meier estimators of different measures of survival failed to show prognostic significance of Vav3.1 in endometrial cancer. Lack of prognostic value was observed for both type 1 and type 2 cancers.Conclusions: Our study shows that Vav3.1 is not suited as a marker of cancer progression and/or treatment response in endometrial cancer. Feasibility and potential benefit of targeting Vav3.1 in endometrial cancer needs to be evaluated in future studies, proceeding from its clear, roughly ten-fold, induction in the malignant endometrium. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Cancer Research & Clinical Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder